Research and Markets: Global Moderate Pain Therapeutics Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/8dmr3h/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• A. Menarini Industrie Farmaceutiche Riunite Srl
• Amorsa Therapeutics Inc.
• Charleston Laboratories, Inc.
• Egalet Corporation
• Elite Pharmaceuticals, Inc.
• KemPharm, Inc.
• Laboratorios Del Dr. Esteve S.A.
• Lumosa Therapeutics Co., Ltd.
• Nektar Therapeutics
• Pacira Pharmaceuticals, Inc.
• Pain Therapeutics, Inc.
• Pfizer Inc.
• Purdue Pharma L.P.
• Relmada Therapeutics, Inc.
• Teva Pharmaceutical Industries Limited
• Trevena, Inc.

For more information visit http://www.researchandmarkets.com/research/8dmr3h/moderate_pain.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005394/en/